GH Research PLC
Develops mebufotenin-based therapies for psychiatric and neurological disorders.
GHRS | US
Overview
Corporate Details
- ISIN(s):
- IE000GID8VI0
- LEI:
- Country:
- United States of America
- Address:
- JOSHUA DAWSON HOUSE, DUBLIN 2
- Website:
- http://www.ghres.com
Description
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to developing therapies for psychiatric and neurological disorders. The company's pipeline is centered on its novel and proprietary mebufotenin (5-MeO-DMT) product candidates. Its lead program, GH001, is an inhaled formulation of mebufotenin being developed for treatment-resistant depression (TRD). Other clinical programs are exploring treatments for bipolar II disorder with a depressive episode and postpartum depression. The company aims to deliver therapies with faster onset of action, durable effects, and improved remission rates. GH Research owns a growing intellectual property portfolio related to mebufotenin's therapeutic applications, formulations, and manufacturing methods.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all GH Research PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GH Research PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GH Research PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
